Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancre...
Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
About this item
Full title
Author / Creator
Kang, Sora , Yoo, Changhoon , Lee, So Heun , Oh, Dongwook , Song, Tae Jun , Lee, Sang Soo , Jeong, Jae Ho , Park, Do Hyun , Seo, Dong Wan , Park, Jin-hong , Hwang, Dae Wook , Song, Ki Byung , Lee, Jae Hoon , Lee, Woohyung , Kwak, Bong Jun , Hong, Sarang , Chang, Heung-Moon , Ryoo, Baek-Yeol , Kim, Kyu-pyo and Kim, Song Cheol
Publisher
London, England: SAGE Publications
Journal title
Language
English
Formats
Publication information
Publisher
London, England: SAGE Publications
Subjects
More information
Scope and Contents
Contents
Background:
Adjuvant chemotherapy is the standard treatment after curative-intent surgery for pancreatic ductal adenocarcinoma (PDAC). The phase-3 ESPAC-4 trial demonstrated significantly improved overall survival (OS) with Gemcitabine plus capecitabine (GemCap) over Gemcitabine (Gem) in Europe. We conducted a retrospective efficacy and safety e...
Alternative Titles
Full title
Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9092583
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9092583
Other Identifiers
ISSN
1758-8359,1758-8340
E-ISSN
1758-8359
DOI
10.1177/17588359221097190
